애리조나의 크론병 임상 시험
크론병 관련 연구 16개가 애리조나 내 여러 지역에서 참여자를 모집하고 있습니다.
애리조나의 도시
공식 연구 텍스트(영어)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- GI Alliance - Sun City ( Site 5118), Sun City
- University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson
피험자 모집 중3상
16세 ~ 80세 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06430801A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- AZ Gastro Care, Chandler
- Research Solutions of Arizona, Litchfield Park
- Mayo Clinic, Scottsdale
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07196722A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Mayo Clinic, Scottsdale
- GIA Sun City, Sun City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07577843A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Investigational Site Number: 8400024, Tucson
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT06958536A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- AZ Gastro Care, Chandler
- Spectrum Research Institute LLC, Gilbert
- GI Alliance- Sun City, Sun City
피험자 모집 중4상
18세 ~ 80세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Elite Clinical Studies /ID# 280477, Phoenix
- Gi Alliance - Arizona Digestive Health - Sun City /ID# 284084, Sun City
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT07697456An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Onyx Clinical Research - Site Number:8400021, Peoria
- One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061, Scottsdale
- Scottsdale Clinical Trials-Site Number: 8400145, Scottsdale
- 외 1개
피험자 모집 중3상
16세 ~ 80세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Phoenix Children's Hospital /ID# 255766, Phoenix
피험자 모집 중3상
2세 ~ 17세 · 모든 성별 · 2026. 10. 20. 업데이트됨 · NCT05995353A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
피험자 모집 중3상
2세 ~ 17세 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06405087Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Mayo Clinic Arizona, Scottsdale
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 8. 7. 업데이트됨 · NCT05230173A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Phoenix Children's Hospital, Phoenix
피험자 모집 중3상
2세 ~ 17세 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06100289A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix
피험자 모집 중3상
2세 이상 · 모든 성별 · 2026. 5. 7. 업데이트됨 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
피험자 모집 중3상
2세 ~ 17세 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Scottsdale Gastroenterology Specialists, Scottsdale
- GI Alliance -Gurnee, Sun City
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 4. 27. 업데이트됨 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Scottsdale
- Mirador Therapeutics Selected Site, Sun City
피험자 모집 중2상
18세 ~ 80세 · 모든 성별 · 2026. 3. 12. 업데이트됨 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Mayo Clinic Arizona, Scottsdale
피험자 모집 중1/2상
18세 ~ 65세 · 모든 성별 · 2025. 12. 10. 업데이트됨 · NCT06721962ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.